RCSI and UCD study identifies immune markers to reduce unnecessary chemotherapy in breast cancer patients
Summary
Research led by RCSI University of Medicine and Health Sciences and University College Dublin has identified immune markers that could help doctors more accurately determine which early-stage ER+HER2- breast cancer patients are unlikely to benefit from chemotherapy. This discovery could spare some patients from unnecessary chemotherapy and its side effects. ER+HER2- breast cancer accounts for approximately 70% of all breast cancer diagnoses annually.
Source
bskyRCSI and UCD study identifies immune markers to reduce unnecessary chemotherapy in breast cancer patientsrcsi.comKey quotes
· 3 pulledResearch led by RCSI University of Medicine and Health Sciences and University College Dublin (UCD) has identified immune markers that could help doctors more accurately determine which breast cancer patients are unlikely to benefit from chemotherapy, potentially sparing some patients from unnecessary treatment.
Chemotherapy is regularly used in the treatment of early-stage, ER+HER2- breast cancer, which accounts for around 70% of all breast cancer diagnoses annually.
While it remains an important treatment, the side effects can...
You might also wanna read
Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic
rockefeller.edu·9mo ago
Scientists Develop Universal Cancer Vaccine Using mRNA Technology
Scientists have developed a 'universal cancer vaccine' using mRNA technology that can train the immune system to target any type of cancer,
newatlas.com·11mo ago
New plasma proteomics model improves thrombosis risk prediction in cancer patients and identifies IL-17-driven endothelial activation as therapeutic target
This article presents research by Karagkouni and colleagues who developed a new cancer-associated venous thromboembolism (VTE) prediction mo
scim.ag·23h ago
Gemma-Based AI Model Identifies Potential Cancer Therapy Pathway Through Conditional Immune Amplification
Researchers used a new 27 billion parameter foundation model called C2S-Scale 27B, built on Google's Gemma family of open models, to discove
blog.google·8mo ago
Navigating Biomarker Conversations: Empowering Patient Understanding in Gastroesophageal Cancer
mdsc.pe·4d ago
Breast Cancer Treatment Strategies: AI ± CDK4/6 Inhibitors, Biomarkers, and ESR1 Mutations
This article appears to be a medical education piece focused on breast cancer treatment strategies, specifically discussing patients progres
mdsc.pe·1d agoComments
Sign in to join the conversation.
No comments yet. Be the first.